Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.
Ferric maltol was granted FDA Approval on 25 July 2019.
Ferric maltol is indicated to treat iron deficiency in adults.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.